Early tacrolimus exposure does not impact long-term outcomes after liver transplantation

Table 2 Recipients outcomes after liver transplantation

	≤ 10 ng/mL, n = 98	> 10 ng/mL, n = 57	P value
Biopsy-proven acute rejection	12 (12.2%)	5(8.8%)	0.505
Arterial complications	12 (12.2%)	7(12.3%)	0.995
Biliary complications	13 (13.3%)	8 (14%)	0.893
Infection (any)	49(50.0%)	26 (45.6%)	0.598
Cytomegalovirus infection	26 (26.5%)	12 (21.1%)	0.445
Retransplantation	5 (5.1%)	5 (8.8%)	0.500
HCC recurrence1	1 (2.3%)	0	0.999
HCV recurrence2	35 (87.5%)	14 (77.8%)	0.438
De novo tumor	10 (10.2%)	5 (8.8%)	0.771
New-onset arterial hypertension	35(36.1%)	19 (36.5%)	0.827
New-onset diabetes	21 (21.6%)	6 (12.7%)	0.127
Tacrolimus withdrawal. Causes:	18 (18.4%)	8 (14.0%)	0.486
Kidney failure	7	1
Neurotoxicity	1	2
Metabolic syndrome	6	4
Metabolic synd + kidney failure	1	-
Other	3	1
MDRD-4 at 5 yr (mean ± SD)	82.5 ± 19.4	80.32 ± 14.7	0.686
Deaths. Causes:	10 (10.2%)	8 (14.0%)	0.827
HCV recurrence	5	3
De novo tumor	1	2
Sepsis	2	1
Stroke	0	1
Other	2	1

¹Including variables with P < 0.2 in univariate analysis, highlighted in bold.

²Renal dysfunction during hospitalization. HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; MDRD-4 stands for: Modification of Diet in Renal Disease.